Photo of Gregory A. Morris, Ph.D.Photo of Gregory A. Morris, Ph.D.

Gregory A. Morris, Ph.D.

Leader, Life Sciences Litigation Practice Group


Fordham University School of Law, J.D.
  • Fordham Intellectual Property Media & Entertainment Law Journal, Associate Editor
Northwestern University, Ph.D.
  • Organic Chemistry
University of Michigan, B.A.
  • English Literature

Prior Employment

  • Kirkland & Ellis LLP, Partner
  • Fish & Neave LLP, Associate/Patent Agent

Bar Admissions

Court Admissions

Professional Affiliations

Intellectual Property Owners Association

New York Intellectual Property Law Association

The Richard Linn American Inn of Court

News & Resources


Gregory is the Leader of Honigman's Life Sciences Litigation practice group. He holds a Ph.D. in Organic Chemistry from Northwestern University. Gregory focuses on pharmaceutical and biotechnology patent litigation, including trial proceedings before the U.S. Patent and Trademark Office (USPTO). He has extensive experience representing clients in Hatch-Waxman litigation. He was also part of a team of attorneys who represented a pharmaceutical company in the first-ever successful defense of an Orange Book-listed patent in an IPR review.

In addition, Gregory is a registered patent attorney and has experience in patent strategy and due diligence work. He has been quoted in the media and writes and lectures widely on patent issues, Hatch-Waxman litigation, and the PTAB.


Significant representative matters include:

  • Supernus Pharmaceuticals: Trial counsel for patentee, Supernus, in three IPRs filed by Amneal Pharmaceuticals who was seeking to sell generic Oracea®. Obtained first win after final written decision for a pharmaceutical company in an IPR proceeding, upholding the validity of three patents. (Petition for Inter Partes Review by Amneal Pharms. LLC, IPR2013-00368, IPR2013-00371, IPR2013-00372 (PTAB))
  • Galderma Labs. and Supernus Pharmaceuticals: Litigation counsel for Galderma and Supernus in ANDA case against Amneal Pharmaceuticals who was seeking to sell generic Oracea®. (Galderma Labs. et al. v. Amneal Pharms. et al., Civil Action No. 1-11-CV-01106 (D. Del.))
  • Sanofi-Aventis: Trial counsel for Sanofi in ANDA case against multiple applicants seeking to sell generic Uroxatral®. Obtained judgment for client after bench trial. (In re: Alfuzosin Hydrochloride Patent Litigation, Civil Action No. 08-md-1941 (D. Del.))
  • Forest Labs and Lundbeck: Trial counsel for Forest and Lundbeck in ANDA case against multiple applicants seeking to sell generic Lexapro®. Obtained judgment for client after bench trial. (Forest Labs., Inc., et al. v. Ivax Pharmaceuticals Inc. et al., Civil Action No. 03-891 (D. Del.))
  • Alexion Pharmaceuticals: Litigation counsel for Alexion in patent infringement case brought by PDL involving client's humanized antibody drug Soliris®. (PDL Biopharma, Inc. v. Alexion Pharmaceuticals, Inc., Civil Action No. 07-156 (D. Del.))

News & Resources


Seminars & Events


  • LMG Life Sciences, Recognized as a Life Sciences Star, 2017-2018
  • Managing Intellectual Property IP STARS, Recognized as a Patent Star, 2016-2018